Cargando…
A case of schizophrenia with congenital color vision deficiency: From the perspective of color universal design to promote medication adherence
Color‐blindness, or more accurately, color vision deficiency (CVD), which is the inability or decreased ability to distinguish different colors, is one of the commonest visual disorders. Patients with schizophrenia usually have multiple types of visual processing impairments, including color vision...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9515716/ https://www.ncbi.nlm.nih.gov/pubmed/35751444 http://dx.doi.org/10.1002/npr2.12278 |
_version_ | 1784798547640582144 |
---|---|
author | Miyazaki, Kensuke Uchiyama, Michiko Tsushima, Chieko Fujimoto, Kentarou |
author_facet | Miyazaki, Kensuke Uchiyama, Michiko Tsushima, Chieko Fujimoto, Kentarou |
author_sort | Miyazaki, Kensuke |
collection | PubMed |
description | Color‐blindness, or more accurately, color vision deficiency (CVD), which is the inability or decreased ability to distinguish different colors, is one of the commonest visual disorders. Patients with schizophrenia usually have multiple types of visual processing impairments, including color vision impairments. Here, we present a case of schizophrenia with congenital CVD. The patient was aware of his color deficiency since elementary school. We assessed his ability to distinguish medicines based on their color, including those that he had been previously prescribed. Although he could distinguish all of the tablets, he could not distinguish the color of the blister packs, specifically that of the bromazepam 2 mg pack (green) from the 1 mg pack (red). This case suggests that CVD patients might misunderstand the color of medications, which might lead to medication errors, or poor drug adherence. The color universal design principle should be considered when designing tablets and their blister packs, in order to improve medication adherence. |
format | Online Article Text |
id | pubmed-9515716 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-95157162022-10-05 A case of schizophrenia with congenital color vision deficiency: From the perspective of color universal design to promote medication adherence Miyazaki, Kensuke Uchiyama, Michiko Tsushima, Chieko Fujimoto, Kentarou Neuropsychopharmacol Rep Case Reports Color‐blindness, or more accurately, color vision deficiency (CVD), which is the inability or decreased ability to distinguish different colors, is one of the commonest visual disorders. Patients with schizophrenia usually have multiple types of visual processing impairments, including color vision impairments. Here, we present a case of schizophrenia with congenital CVD. The patient was aware of his color deficiency since elementary school. We assessed his ability to distinguish medicines based on their color, including those that he had been previously prescribed. Although he could distinguish all of the tablets, he could not distinguish the color of the blister packs, specifically that of the bromazepam 2 mg pack (green) from the 1 mg pack (red). This case suggests that CVD patients might misunderstand the color of medications, which might lead to medication errors, or poor drug adherence. The color universal design principle should be considered when designing tablets and their blister packs, in order to improve medication adherence. John Wiley and Sons Inc. 2022-06-25 /pmc/articles/PMC9515716/ /pubmed/35751444 http://dx.doi.org/10.1002/npr2.12278 Text en © 2022 The Authors. Neuropsychopharmacology Reports published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Society of Neuropsychopharmacology. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Case Reports Miyazaki, Kensuke Uchiyama, Michiko Tsushima, Chieko Fujimoto, Kentarou A case of schizophrenia with congenital color vision deficiency: From the perspective of color universal design to promote medication adherence |
title | A case of schizophrenia with congenital color vision deficiency: From the perspective of color universal design to promote medication adherence |
title_full | A case of schizophrenia with congenital color vision deficiency: From the perspective of color universal design to promote medication adherence |
title_fullStr | A case of schizophrenia with congenital color vision deficiency: From the perspective of color universal design to promote medication adherence |
title_full_unstemmed | A case of schizophrenia with congenital color vision deficiency: From the perspective of color universal design to promote medication adherence |
title_short | A case of schizophrenia with congenital color vision deficiency: From the perspective of color universal design to promote medication adherence |
title_sort | case of schizophrenia with congenital color vision deficiency: from the perspective of color universal design to promote medication adherence |
topic | Case Reports |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9515716/ https://www.ncbi.nlm.nih.gov/pubmed/35751444 http://dx.doi.org/10.1002/npr2.12278 |
work_keys_str_mv | AT miyazakikensuke acaseofschizophreniawithcongenitalcolorvisiondeficiencyfromtheperspectiveofcoloruniversaldesigntopromotemedicationadherence AT uchiyamamichiko acaseofschizophreniawithcongenitalcolorvisiondeficiencyfromtheperspectiveofcoloruniversaldesigntopromotemedicationadherence AT tsushimachieko acaseofschizophreniawithcongenitalcolorvisiondeficiencyfromtheperspectiveofcoloruniversaldesigntopromotemedicationadherence AT fujimotokentarou acaseofschizophreniawithcongenitalcolorvisiondeficiencyfromtheperspectiveofcoloruniversaldesigntopromotemedicationadherence AT miyazakikensuke caseofschizophreniawithcongenitalcolorvisiondeficiencyfromtheperspectiveofcoloruniversaldesigntopromotemedicationadherence AT uchiyamamichiko caseofschizophreniawithcongenitalcolorvisiondeficiencyfromtheperspectiveofcoloruniversaldesigntopromotemedicationadherence AT tsushimachieko caseofschizophreniawithcongenitalcolorvisiondeficiencyfromtheperspectiveofcoloruniversaldesigntopromotemedicationadherence AT fujimotokentarou caseofschizophreniawithcongenitalcolorvisiondeficiencyfromtheperspectiveofcoloruniversaldesigntopromotemedicationadherence |